flu Beyond the lungs: study Reveals High Rate of Non-Respiratory Complications in Hospitalized Children
Table of Contents
A new study presented at IDWeek 2025 reveals that influenza poses a far greater threat to children than previously understood, with a ample number experiencing severe complications extending beyond the respiratory system. The findings underscore the need for heightened clinical vigilance, particularly regarding vaccination and antiviral treatment, among healthcare professionals including pharmacists and inpatient care teams.
Over a decade of surveillance thru the influenza Hospitalization Surveillance Network (FluSurv-NET) has demonstrated a concerning trend: while influenza is widely recognized as a respiratory virus, a important proportion of hospitalized children suffer serious non-respiratory complications. Researchers analyzed data from 2010-2011 to 2022-2023, encompassing 17,442 children under 18 hospitalized with laboratory-confirmed influenza.
Children With Non-Respiratory Presentations Differ Clinically
Children presenting with solely non-respiratory diagnoses differed substantially from those with respiratory involvement. Thay where, on average, older – a median age of 5.1 years compared to 2.6 years (P < .0001) – and more likely to be infected with influenza B (32% vs. 23%; P < .0001). Moreover, they had a higher probability of pre-existing medical conditions (59% vs. 53%; P = .015). Despite their higher risk profile, thes children were demonstrably less likely to receive antiviral therapy (38% vs. 63%; P < .001). “Delayed recognition of influenza when symptoms do not correspond to the expected respiratory presentation may explain this substantial difference in treatment,” a senior researcher noted. This highlights a critical gap in care for frontline clinicians and pharmacists responsible for initiating antiviral treatment.
Severe Outcomes Associated With Multi-Organ Involvement
The FluSurv-NET analysis revealed that non-respiratory inflammatory-related diagnoses significantly increased morbidity. Children experiencing sepsis,acute kidney injury,or cardiovascular complications faced substantially higher rates of intensive care unit (ICU) admission,mechanical ventilation,and in-hospital mortality. For example, children with sepsis had a median hospital stay of 3.9 days, with 31% requiring mechanical ventilation and a 5.2% in-hospital mortality rate. Cardiovascular complications carried the highest mortality rate, reaching nearly 19.7%. These findings align with existing data indicating that systemic and neurologic complications, such as encephalopathy and acute necrotizing encephalopathy, can lead to severe and lasting consequences, including neurological damage and death.
A comprehensive analysis of pediatric influenza complications across various seasons confirms the frequent occurrence of multi-system involvement.According to reports from the CDC, neurological complications like influenza-associated encephalopathy (IAE) and acute necrotizing encephalopathy (ANE) are major contributors to increased pediatric mortality in recent seasons, demonstrating the flu’s potential severity even when it doesn’t primarily affect the respiratory tract..
Clinical Implications for Pharmacists and Healthcare Teams
Pharmacists play a vital role in mitigating the impact of influenza. Worldwide immunization, recommended for all children aged 6 months and older, remains the cornerstone of prevention. Declines in pediatric influenza vaccination coverage are a growing concern, particularly given the elevated rates of non-respiratory complications. Ensuring robust advocacy for vaccination, especially among children with underlying medical conditions, is paramount.
The underutilization of antivirals in children presenting with non-respiratory symptoms underscores the importance of early empiric antiviral therapy for all hospitalized children suspected of having influenza, regardless of their initial symptoms. Evidence from previous pandemic research supports early antiviral initiation to prevent severe complications, particularly in high-risk children.
this extensive, multi-season study of a large pediatric cohort has definitively shown that a considerable number of hospitalized children develop non-respiratory complications from influenza, some carrying very high rates of morbidity and mortality. Children whose initial presentation is non-respiratory are older, more likely to have underlying medical conditions, frequently enough infected with influenza B, and less likely to receive antiviral medications. Enhanced recognition of these non-respiratory manifestations, coupled with optimal vaccination rates and timely antiviral therapy, can serve as crucial prevention strategies and improve clinical outcomes for pediatric patients.
